Oct 21, 2007 - Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, announced detailed results at the 24 week primary endpoint of its Phase IIb trial of Empatic, one of its two obesity drug candidates*... Orexigen's Press Release-
Tuesday, October 23, 2007
Orexigen Therapeutics, Phase IIb Trial of Empatic to Treat Obesity
Oct 21, 2007 - Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, announced detailed results at the 24 week primary endpoint of its Phase IIb trial of Empatic, one of its two obesity drug candidates*... Orexigen's Press Release-
